Carbidopa/oxitriptan (developmental code name EVX-101), or carbidopa/5-hydroxytryptophan (carbidopa/5-HTP), is a combination of 5-hydroxytryptophan (oxitriptan), a serotonin precursor, and carbidopa, a peripherally selective aromatic L-amino acid decarboxylase inhibitor, which is under development as an antidepressant for the treatment of depressive disorders.[1] As of June 2020, it is in phase 1 clinical trials for this indication.[1]
 | |
.svg) Carbidopa (top) and oxitriptan (bottom) | |
| Combination of | |
|---|---|
| Carbidopa | Aromatic L-amino acid decarboxylase inhibitor |
| Oxitriptan | Serotonin precursor |
| Clinical data | |
| Other names | Carbidopa/5-hydroxytryptophan; Carbidopa/L-5-hydroxytryptophan; Carbidopa/5-HTP; Carbidopa/L-5-HTP; EVX-101 |
| Routes of administration | Oral administration |
References
edit- ^ a b "Carbidopa/oxytriptan - Evecxia". AdisInsight. Springer Nature Switzerland AG.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |